Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1132 articles by Jacob Bell
-
How Gilead finally spent its money
Nov. 24, 2020 -
Lilly dives into gene editing
Nov. 20, 2020 -
Stem cell therapy for ALS fails a large clinical trial
Nov. 17, 2020 -
Japanese drugmaker takes full control of a Roivant biotech
Nov. 13, 2020 -
Amgen's asthma drug delivers a needed win
Nov. 10, 2020 -
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
Nov. 9, 2020 -
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Nov. 6, 2020 -
Biogen surges as FDA reviewers appear supportive of Alzheimer's drug approval
Nov. 4, 2020 -
The meeting that could change Alzheimer's treatment
Nov. 3, 2020 -
Regeneron pauses study of rare disease drug following patient deaths
Nov. 2, 2020 -
Novartis eyes its next move in gene therapy
Oct. 29, 2020 -
Bristol Myers taps machine-learning biotech for help finding ALS drugs
Oct. 28, 2020 -
Sarepta, continuing its gene therapy push, helps launch a startup
Oct. 22, 2020 -
Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales
Oct. 21, 2020 -
Biogen is running out of safety nets
Oct. 21, 2020 -
Early signs of survival benefit raise optimism around a small biotech's ALS drug
Oct. 16, 2020 -
Vertex faces first notable setback as it pushes beyond cystic fibrosis
Oct. 14, 2020 -
Gossamer plummets as its lead drug fails 2 studies
Oct. 13, 2020 -
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Oct. 8, 2020 -
With a sweetened offer, BridgeBio plans to reel in a subsidiary
Oct. 5, 2020 -
Pfizer pushes deeper into China with stake in cancer biotech
Sept. 30, 2020 -
Biogen's all-important Alzheimer's drug enters the review gauntlet
Sept. 29, 2020 -
After setback in the US, Galapagos' main drug finds success elsewhere
Sept. 28, 2020 -
GSK inhaler locks down a coveted approval in asthma
Sept. 10, 2020 -
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
Sept. 10, 2020